Tango Therapeutics (TNGX) CFO reports RSUs, option grant and tax sale

Rhea-AI Filing Summary

Tango Therapeutics Chief Financial Officer Daniella Beckman reported new equity awards and related tax sales. On February 2, 2026, she acquired 44,330 shares of common stock for $0, representing restricted stock units that vest in three tranches through February 2029, and received a stock option for 265,980 shares at an exercise price of $11.94 per share, vesting over four years.

On February 3, 2026, she sold 10,204 and 113 shares of common stock at weighted average prices of $12.2573 and $12.8971, respectively, under the company’s automatic “sell-to-cover” policy for tax withholding tied to RSU vesting. After these transactions, she held 184,297 shares of common stock and 265,980 stock options, all reported as directly owned.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Beckman Daniella

(Last) (First) (Middle)

C/O TANGO THERAPEUTICS, INC.,

201 BROOKLINE AVE., SUITE 901

(Street)

BOSTON MA 02215

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		A		44,330(1)	A	$0	194,614	D
Common Stock	02/03/2026		S(2)		10,204	D	$12.2573(3)	184,410	D
Common Stock	02/03/2026		S(2)		113	D	$12.8971(4)	184,297	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.94	02/02/2026		A		265,980		(5)	02/02/2036	Common Stock	265,980	$0	265,980	D

Explanation of Responses:

1. These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

2. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

3. Represents the weighted average sales price per share. The shares sold at prices ranging from $11.88 to $12.875 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

4. Represents the weighted average sales price per share. The shares sold at prices ranging from $12.88 to $12.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

5. This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2027 with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

	/s/ Daniella Beckman	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Tango Therapeutics (TNGX) CFO report?

The CFO reported new equity awards and small stock sales. She received restricted stock units and a large stock option grant, then sold a limited number of shares to cover tax withholding obligations tied to vesting, while retaining a substantial direct equity position in Tango Therapeutics.

How many Tango Therapeutics (TNGX) shares does the CFO hold after these trades?

After the reported transactions, the CFO directly holds 184,297 shares of common stock. She also holds a stock option for 265,980 shares, providing additional potential equity exposure if the options vest and are later exercised under their stated terms.

What equity awards did the Tango Therapeutics (TNGX) CFO receive?

She received 44,330 restricted stock units, each representing one common share, and a stock option covering 265,980 shares at an exercise price of $11.94. The RSUs vest over three years, while the option vests over four years, subject to continued service.

When do the Tango Therapeutics (TNGX) CFO’s RSUs vest?

The RSUs vest in three installments: 33% on February 1, 2027, 33% on February 14, 2028, and 34% on February 12, 2029. Vesting is conditioned on her continuous service with Tango Therapeutics through each specified vesting date.

Why did the Tango Therapeutics (TNGX) CFO sell shares on February 3, 2026?

The sales were executed under Tango Therapeutics’ “sell-to-cover” policy. Shares were sold solely to satisfy tax withholding obligations triggered by vesting restricted stock units and were automatic, not discretionary trades initiated for portfolio or liquidity reasons.

What are the terms of the Tango Therapeutics (TNGX) CFO’s new stock option?

The new option covers 265,980 shares of common stock at an exercise price of $11.94 per share. It vests 25% on January 1, 2027, with the remainder vesting in 36 equal monthly installments, contingent on continued service.